Search

Your search keyword '"Sakata, Y"' showing total 3,452 results
Start Over Author "Sakata, Y"
3,452 results on '"Sakata, Y"'

102. Prognostic value of nutritional status in patients with heart failure with preserved ejection fraction, with and without atrial fibrillation: insights From PURSUIT-HFpEF Registry

Author

Kawasaki, M, primary, Yamada, T, additional, Watanabe, T, additional, Morita, T, additional, Furukawa, Y, additional, Tamaki, S, additional, Kikuchi, A, additional, Kawai, T, additional, Seo, M, additional, Fukunami, M, additional, Yasumura, Y, additional, Hayashi, T, additional, Yano, M, additional, Hikoso, S, additional, and Sakata, Y, additional

Published
2020
Full Text
View/download PDF

104. Role of diuretics on long-term mortality may differ in volume status in patients with acute myocardial infarction

Author

Kawai, T, primary, Nakatani, D, additional, Yamada, T, additional, Watanabe, T, additional, Morita, T, additional, Furukawa, Y, additional, Tamaki, S, additional, Kawasaki, M, additional, Kikuchi, A, additional, Seo, M, additional, Nakamura, J, additional, Hikoso, S, additional, Fukunami, M, additional, and Sakata, Y, additional

Published
2020
Full Text
View/download PDF

105. Sex differences in door-to-balloon time and long-term adverse events after percutaneous coronary intervention for acute coronary syndrome: a sub-study from the Prospective JAMIR study

Author

Kimura, T, primary, Ito, T.I, additional, Honda, S, additional, Nishihira, K, additional, Kojima, S, additional, Takegami, M, additional, Asaumi, Y, additional, Suzuki, M, additional, Kosuge, M, additional, Takahashi, J, additional, Sakata, Y, additional, Takayama, M, additional, Sumiyoshi, T, additional, Kimura, K, additional, and Yasuda, S, additional

Published
2020
Full Text
View/download PDF

106. Serial evaluation of cardiac allograft vasculopathy after heart transplantation by dual-modality intravascular ultrasound and optical coherence tomography

Author

Shiraki, T, primary, Ohtani, T, additional, Kioka, H, additional, Mizote, I, additional, Tsukamoto, Y, additional, Nakamura, D, additional, Yokoi, K, additional, Ide, S, additional, Nakamoto, K, additional, Takeda, Y, additional, Hikoso, S, additional, Sawa, Y, additional, and Sakata, Y, additional

Published
2020
Full Text
View/download PDF

122. P-98 HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer

Author

Ando, T., primary, Ito, K., additional, Yuki, S., additional, Saito, R., additional, Nakano, S., additional, Nakatsumi, H., additional, Kawamoto, Y., additional, Dazai, M., additional, Miyashita, K., additional, Hatanaka, K., additional, Harada, K., additional, Miyagishima, T., additional, Hisai, H., additional, Ishiguro, A., additional, Ueda, A., additional, Kato, T., additional, Sasaki, T., additional, Shindo, Y., additional, Yokota, I., additional, Takagi, R., additional, Sakata, Y., additional, and Komatsu, Y., additional

Published
2020
Full Text
View/download PDF

123. P-112 HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody

Author

Shindo, Y., primary, Nakatsumi, H., additional, Yuki, S., additional, Kawamoto, Y., additional, Muto, O., additional, Dazai, M., additional, Harada, K., additional, Kobayashi, Y., additional, Sogabe, S., additional, Katagiri, M., additional, Kotaka, M., additional, Nakamura, M., additional, Hatanaka, K., additional, Ishiguro, A., additional, Tsuji, Y., additional, Kobayashi, T., additional, Tateyama, M., additional, Sasaki, Y., additional, Sasaki, T., additional, Takagi, R., additional, Sakata, Y., additional, and Komatsu, Y., additional

Published
2020
Full Text
View/download PDF

128. HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)

Author

Tanimoto, A., primary, Yagisawa, M., additional, Nakano, S., additional, Kawamoto, Y., additional, Yuki, S., additional, Ishiguro, A., additional, Takahata, T., additional, Sato, A., additional, Iwanaga, I., additional, Ehira, N., additional, Uebayashi, M., additional, Muto, O., additional, Sasaki, T., additional, Hatanaka, K., additional, Tateyama, M., additional, Wakabayashi, T., additional, Dazai, M., additional, Minami, S., additional, Sakata, Y., additional, and Komatsu, Y., additional

Published
2019
Full Text
View/download PDF

129. Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)

Author

Sasaki, Y., primary, Muranaka, T., additional, Kawamoto, Y., additional, Sawada, K., additional, Nakatsumi, H., additional, Harada, K., additional, Miyagishima, T., additional, Hatanaka, K., additional, Dazai, M., additional, Ueda, A., additional, Sasaki, T., additional, Shinada, K., additional, Tsuji, Y., additional, Yuki, S., additional, Sakamoto, N., additional, Nishimoto, N., additional, Sakata, Y., additional, and Komatsu, Y., additional

Published
2019
Full Text
View/download PDF

133. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Author

Sands, B. E., Sandborn, W. J., Panaccione, R., O'Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M. T., Hisamatsu, T., Szapary, P., Brown S, Marano C., Connor, S, De Cruz, P, Ding, Nj, Florin, T, Hendy, P, Leong, R, Moore, G, Pavli, P, Sparrow, M, Gassner, S, Vogelsang, H, Baert, F, Colard, A, De Vos, M, D'Heygere, F, Ferrante, M, Louis, E, Staessen, D, Berova, T, Churchev, J, Draganova, R, Gancheva, D, Ivanova, N, Marinova, I, Markov, M, Nikolov, R, Tsonev, N, Vassileva, G, Afif, W, Berstein, C, Bressler, B, Jairath, V, Lachance, Jr, Singh, R, Tilbe, K, Komarek, V, Kozeluhova, J, Lukas, M, Volfova, M, Dahlerup, J, Altwegg, R, Beorchia, S, Bouguen, G, Cadiot, G, Dupas, Jl, Desreumaux, P, Flourie, B, Grimaud, Jc, Guillaud, O, Moreau, J, Roblin, X, Zerbib, F, Baumgart, D, Beckebaum, S, Bokemeyer, B, Ebert, M, Hasselblatt, P, Lügering, A, Maaser, C, Schiefke, I, Schreiber, S, Seidler, U, Altorjay, I, Kiss, Gg, Literati-Nagy, B, Patai, A, Pecsi, G, Salamon, A, Schnabel, R, Székely, A, Tulassay, Z, Varga, M, Fich, A, Fishman, S, Konikoff, F, Lichtenstein, L, Rainis, T, Sbeit, W, Schwartz, D, Annese, V, Biancone, L, Bossa, F, Costintino, R, Danese, S, Fries, W, Gasbarrini, A, Guidi, L, Kohn, A, Maconi, G, Rocca, R, Rogai, F, Villa, E, Zoli, G, Akiho, H, Aoyama, N, Arisawa, T, Hidaka, H, Hisamatsu, T, Horiki, N, Inaba, T, Inoue, S, Ishida, T, Ishida, H, Ishiguro, Y, Ishihara, S, Iwabuchi, M, Kato, J, Katsushima, S, Kobayashi, T, Kojima, Y, Kurihara, H, Masuo, T, Matsui, T, Matsumoto, T, Matsuoka, K, Mitsuyama, K, Motoya, S, Nakagawa, T, Nakai, K, Nakamura, S, Niihara, T, Ohnishi, Y, Ohta, A, Osada, T, Ryuichi, I, Sakai, Y, Sakata, Y, Sameshima, Y, Sano, K, Shibatoge, M, Shibuya, T, Suzuki, Y, Takeshima, F, Tanaka, S, Taruishi, M, Tokito, S, Ueo, T, Watanabe, K, Yamagami, H, Cheon, Jh, Cho, Kb, Knowles, Kim, Kim, Hj, Kim, Y, Lee, Km, Yang, Sk, D'Haens, G, Pierik, M, Gearry, R, Inns, S, Rowbotham, D, Schultz, M, Bochenek, A, Gawdis-Wojnarska, B, Kleczkowski, D, Leszczyszyn, J, Malecka-Panas, E, Mamos, A, Petryka, R, Regula, J, Rozciecha, J, Stefanuik, P, Wozniak-Stolarska, B, Cimpoeru, N, Craciun, E, Ovidiu, Cf, Goldis, E, Ionita-Radu, F, Lazar, D, Suciu, I, Abdulkhakov, R, Alikhanov, B, Apartsin, K, Bakulin, I, Belousova, E, Gofman, A, Grinevich, V, Kulyapin, A, Nizov, A, Osipenko, M, Simanenkov, V, Tkachev, A, Uspenskiy, Y, Valuyskikh, E, Jovanovic, I, Nagorni, A, Svorcan, P, Zdravkovic, N, Bunganic, I, Abrahamovych, O, Bilianskyi, L, Datsenko, O, Golovchenko, O, Kharchenko, N, Klymenko, V, Levchenko, O, Lozynskyy, Y, Murenets, N, Oliinyk, O, Prystupa, L, Pyrogovskyi, V, Reznikova, V, Rishko, I, Stanislavchuk, M, Vizir, V, Yatsyshyn, R, Arasaradnam, R, Bloom, S, Cummings, F, Iqbal, T, Irving, P, Kaser, A, Shonde, A, Subramanian, S, Aberra, F, Aguilar, H, Araya, V, Bakken, A, Beaulieu, D, Cappa, Ja, Chiorean, M, Cohen, N, Dryden, G, Duvall, G, Ehrlich, A, Eisner, M, Ertan, A, Fogel, R, Friedenberg, K, Gatof, D, Glover, S, Grosman, I, Gunaratnam, N, Gupta, N, Haynes, P, Hemaidan, A, Higgins, P, Hou, J, Hudesman, D, Iskandar, H, Jazrawi, S, Jones, M, Karnam, U, Khurana, S, Killpack, M, Kreines, M, Lawlor, G, Lee, S, Loftus, E, Lukin, Dj, Marcet, J, Mattar, M, Melmed, G, Minor, T, Mirkin, K, Mutlu, E, Nichols, M, Nudell, J, Rai, R, Ramos, C, Mcleod, Randall, Rausher, D, Ritter, T, Singh Saini, S, Salzberg, B, Saubermann, L, Scherl, E, Sedghi, S, Sellin, J, Shafran, I, Sorrentino, D, Suiter, D, Swaminath, A, Tiongco, F, Vrabie, R, Walp, K, Warner, N, Winstead, N, Wolf, Dc, Woods, J, Yen, E, Younes, Z., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Maag Darm Lever (9), Interne Geneeskunde, Sands, Be, Sandborn, Wj, Panaccione, R, O'Brien, Cd, Zhang, H, Johanns, J, Adedokun, Oj, Li, K, Peyrin-Biroulet, L, Van Assche, G, Danese, S, Targan, S, Abreu, Mt, Hisamatsu, T, Szapary, P, and Marano, C

Subjects
Adult, Male, Infusions, [SDV]Life Sciences [q-bio], Injections, Subcutaneous, Anti-Inflammatory Agents, Ulcerative, Klinikai orvostudományok, Article, Injections, Maintenance Chemotherapy, Dose-Response Relationship, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, INFLIXIMAB, Colitis, Ulcerative, Dose-Response Relationship, Drug, Female, Humans, Induction Chemotherapy, Infusions, Intravenous, Patient Acuity, Remission Induction, Ustekinumab, ComputingMilieux_MISCELLANEOUS, ACTIVITY INDEXES, Subcutaneous, Orvostudományok, General Medicine, EFFICACY, Colitis, 3. Good health, INFECTIONS, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Drug, Intravenous
Abstract

The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.We evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy in patients with moderate-to-severe ulcerative colitis. A total of 961 patients were randomly assigned to receive an intravenous induction dose of ustekinumab (either 130 mg [320 patients] or a weight-range-based dose that approximated 6 mg per kilogram of body weight [322]) or placebo (319). Patients who had a response to induction therapy 8 weeks after administration of intravenous ustekinumab were randomly assigned again to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 12 weeks [172 patients] or every 8 weeks [176]) or placebo (175). The primary end point in the induction trial (week 8) and the maintenance trial (week 44) was clinical remission (defined as a total score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe disease] and no subscore1 [range, 0 to 3] on any of the four Mayo scale components).The percentage of patients who had clinical remission at week 8 among patients who received intravenous ustekinumab at a dose of 130 mg (15.6%) or 6 mg per kilogram (15.5%) was significantly higher than that among patients who received placebo (5.3%) (P0.001 for both comparisons). Among patients who had a response to induction therapy with ustekinumab and underwent a second randomization, the percentage of patients who had clinical remission at week 44 was significantly higher among patients assigned to 90 mg of subcutaneous ustekinumab every 12 weeks (38.4%) or every 8 weeks (43.8%) than among those assigned to placebo (24.0%) (P = 0.002 and P0.001, respectively). The incidence of serious adverse events with ustekinumab was similar to that with placebo. Through 52 weeks of exposure, there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esophageal varices) and seven cases of cancer (one each of prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who received ustekinumab and no deaths and one case of cancer (testicular cancer) among 319 patients who received placebo.Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).

Published
2019

146. Neointimal characteristics comparison between biodegradable-polymer and durable-polymer drug-eluting stents: 3-month follow-up optical coherence tomography light property analysis from the RESTORE registry

Author

Kobayashi, T. (Tomoaki), Sotomi, Y. (Yohei), Suzuki, S. (Satoshi), Hamanaka, Y. (Yuma), Nakatani, T. (Tomoya), Dijkstra, J. (Jouke), Onuma, Y. (Yoshinobu), Serruys, P.W.J.C. (Patrick), Sakata, Y. (Yasushi), Hirayama, A. (Atsushi), Higuchi, Y. (Yoshiharu), Kobayashi, T. (Tomoaki), Sotomi, Y. (Yohei), Suzuki, S. (Satoshi), Hamanaka, Y. (Yuma), Nakatani, T. (Tomoya), Dijkstra, J. (Jouke), Onuma, Y. (Yoshinobu), Serruys, P.W.J.C. (Patrick), Sakata, Y. (Yasushi), Hirayama, A. (Atsushi), and Higuchi, Y. (Yoshiharu)

Abstract

We aimed to quantitatively assess a possible difference of the neointimal quality between biodegradable polymer- (BP-) and durable polymer drug-eluting stents (DP-DESs). We conducted a single-center all-comer prospective cohort study: the RESTORE registry (UMIN000033009). All patients who received successful OCT examination at planned 3-month follow-up after DES implantation were analyzed. Study population was divided into 2 groups, BP-DES versus DP-DES groups. We evaluated standard OCT variables, coverage percent, and the quantitative light property values including light intensity, attenuation, and backscatter. We performed OCT analyses of 121 lesions in 98 patients (BP-DES 55 lesions in 51 patients vs. DP-DES 66 lesions in DP-DES 53 patients). Lesion and procedural characteristics were overall well-balanced between both groups. At 3-month follow-up, neointimal thickness (BP-DES 49.3 [38.2, 57.7] µm versus DP-DES 54.7 [45.1, 70.7] µm, p = 0.059) and coverage percent (BP-DES 94.5 [89.8, 97.0]% vs. DP-DES 95.8 [91.1, 98.1]%, p = 0.083) did not significantly differ. Light intensity of superficial neointima in the BP-DES was lower than that in the DP-DES, whereas that of deep neointima did not differ between both groups.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results